SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These ...

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2 ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

Discover a study that explores how PARP inhibition with niraparib may offer new therapeutic potential for advanced melanoma ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Marstacimab is a tissue factor pathway inhibitor antagonist approved under the brand name Hympavzi.

Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration ...

Protein–protein interactions are no longer considered undruggable because of the conceptual and technical advances that allow inhibitors to be generated using rational design principles and ...